€725m for late-stage life sciences: Sofinnova Partners closes Crossover II

By Kai Marek

· VC fund

Sofinnova Partners has closed Crossover II at €725m, above its original target, to back about 15 late-stage life sciences companies, primarily in Europe.

Sofinnova Crossover II

Paris, France

€725m

Reported by sofinnovapartners.com

VC fund

Investment focus

Growth · Health & Bio

United KingdomUkraineTurkeySwitzerlandSwedenSpainSlovakiaSloveniaSerbiaRomaniaPortugalPolandNorwayNetherlandsMontenegroMoldovaMaltaNorth MacedoniaLuxembourgLithuaniaLatviaKosovoItalyIrelandIcelandHungaryGreeceGermanyFranceFinlandEstoniaDenmarkCzech RepublicCyprusCroatiaBulgariaBosniaBelgiumBelarusAustriaAlbaniaParis

As announced by Sofinnova Partners in a press release dated November 16, 2026, the “Sofinnova Crossover II” fund has reached its final close with a total of 725 million euros (815 million US dollars). According to the Paris-based venture capital firm, which specializes in life sciences, the fund has exceeded its original target.

The fund supports life sciences companies in advanced stages of development. Its focus is on European biopharmaceutical and medical technology firms that are in the clinical phase and require capital for the next step toward commercialization. The fund also intends to make selective investments in the United States and other markets. Sofinnova plans to invest in approximately 15 companies; firms already backed by the fund include Hemab Therapeutics, CellCentric, and Neurent Medical.

The only investor mentioned in the announcement is the "European Tech Champions Initiative," a fund of funds managed by the European Investment Fund (EIF). The total number of other participating investors remains undisclosed.

Founded in 1972, Sofinnova operates from offices in Paris, London, and Milan, and reports that it manages assets exceeding 4 billion euros. The firm’s strategy is led by partners Joe Anderson, Kinam Hong, Cedric Moreau, Jacques Theurillat, and David Evans.

The company points to four exits from its first crossover fund: three of these were acquisitions – LimFlow was acquired by Inari Medical, Calliditas Therapeutics by Asahi Kasei, and Amolyt Pharma by AstraZeneca. Abivax also went public on the Nasdaq.

Sources

See all France funds in the tracker